Matthew Gall - Chief Financial Officer at iTeos Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Financial Officer
Stock Symbol
ITOS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
All Insider Reports
All Insider Reports

Matthew Gall - trading volume in the past year for iTeos Therapeutics, Inc.

Holdings reported by Matthew Gall for iTeos Therapeutics, Inc.

Class Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 60.4K $506K $8.37 Dec 5, 2023 Direct
Stock Option (Right to Buy) 163K Mar 7, 2024 Direct Common Stock

Transactions reported by Matthew Gall for iTeos Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.